Share article
For decades, occupational hearing loss was treated as a singular problem: a worker’s ears got worse, audiometric thresholds shifted, and the employer’s liability grew. That framing is now profoundly incomplete. A growing body of peer-reviewed research — including a landmark 2024 Lancet Commission report, a 2024 meta-analysis of 50 studies encompassing more than 1.5 million participants, and a comprehensive PLOS ONE review of 36 cohort studies involving more than 6.3 million people — demonstrates that untreated hearing loss is associated with substantially elevated risks of dementia, cardiovascular disease, depression, falls, hospitalization, long-term care placement, and all-cause mortality. The implications for employers running hearing conservation programs extend far beyond OSHA compliance.
Soundtrace’s audiometric monitoring program detects threshold shifts early — the intervention window when the downstream health trajectory can still be altered.
Every annual audiogram taken under OSHA 1910.95 is a data point in a worker’s long-term health trajectory. A worker who develops a standard threshold shift at age 45 and goes untreated for a decade is not merely accumulating hearing loss — they are accumulating elevated risk for dementia, cardiovascular events, depression, and early mortality. The hearing conservation program is not just a compliance instrument. It is one of the most consequential occupational health interventions an employer operates.
The 2024 update of the Lancet Commission on Dementia Prevention, Intervention, and Care — the most authoritative ongoing review in the field, covering 14 modifiable risk factors — identified hearing loss as the single largest modifiable risk factor for dementia, accounting for approximately 8–9% of dementia cases globally. The Commission’s 2024 report stated: the evidence that treating hearing loss decreases dementia risk is now stronger than when their previous Commission was published.
A 2024 systematic review and meta-analysis published in Ageing Research Reviews, incorporating data from 50 cohort studies encompassing more than 1.5 million participants, found that adult-onset hearing loss was significantly associated with increased risk of cognitive decline, dementia, mild cognitive impairment (MCI), and Alzheimer’s disease. The dose-response relationship is consistent across studies: individuals with mild hearing loss have approximately double the dementia risk of those with normal hearing; moderate loss nearly triples the risk; and severe loss is associated with approximately five times the dementia risk.
A Johns Hopkins/ARIC study published in JAMA in 2023, examining 2,400+ older adults in a nationally representative sample, found that the prevalence of dementia among participants with moderate or severe hearing loss was 61% higher than among those with normal hearing, and that hearing aid use was associated with a 32% lower prevalence of dementia in that group.
A Polish cohort study as part of the PURE study (published 2025) found that mild cognitive impairment was present in nearly 50% of participants with hearing loss, compared to 26% without, with hearing loss increasing the odds of MCI by 34%.
Three primary pathways are proposed to explain the hearing loss–dementia association, and they are not mutually exclusive. First, increased cognitive load: when the brain must allocate disproportionate cognitive resources to process degraded auditory input, those resources are diverted from other cognitive functions including memory consolidation and executive processing. This effortful listening hypothesis is supported by neuroimaging studies showing accelerated structural brain changes in individuals with untreated hearing loss.
Second, social isolation and reduced cognitive engagement: individuals with hearing loss progressively withdraw from communication-intensive social activities, reducing the cognitive stimulation that appears protective against neurodegeneration. Third, shared pathology: hearing loss and dementia may share common vascular and neurobiological mechanisms — particularly cochlear vascular disease and central auditory pathway degeneration — meaning that hearing loss may in some cases be an early marker or early manifestation of the same pathological process that eventually produces clinical dementia.
A 2025 PLOS ONE meta-analysis of 36 cohort studies involving 6,364,914 participants found a statistically significant association between hearing loss and all-cause mortality (HR 1.24, 95% CI 1.05–1.46) and cardiovascular mortality specifically (HR 1.22, 95% CI 1.12–1.33). The association for cancer mortality was also elevated (HR 1.11, 95% CI 1.02–1.22). The cardiovascular mortality finding is consistent across multiple independent study populations.
The Gutenberg Health Study, a population-based cohort of 15,010 participants aged 35–74 years published in Scientific Reports (2025), found that 35% of participants exhibited some degree of hearing loss and documented associations between hearing loss, cardiovascular risk factors, and all-cause mortality using Cox proportional hazards models adjusted for potential confounders.
A large Canadian population-based cohort study of 4,724,646 adults (EClinicalMedicine, 2023) found that hearing loss was associated with significantly elevated rates of myocardial infarction, stroke or transient ischemic attack, and heart failure, in addition to increased all-cause mortality. The study’s scale — nearly 5 million participants — provides unusually robust statistical power for detecting associations that smaller studies might miss.
The research reviewed here establishes associations between hearing loss and adverse health outcomes. Causal mechanisms are proposed but not definitively established for most outcomes. Confounding factors — age, cardiovascular disease, socioeconomic status, overall health behaviors — are partially but not completely controlled in observational studies. The consensus in the research community, as reflected in the 2024 Lancet Commission, is that the associative evidence is now sufficiently robust to support clinical and public health action, while acknowledging that randomized controlled trial evidence for some outcomes remains limited.
The Canadian population-based cohort study of 4.7 million adults found that hearing loss was significantly associated with incident depression as an independent outcome, after adjustment for cardiovascular comorbidities and other confounders. A longitudinal relationship between hearing loss and depression has been replicated across multiple study populations and geographic settings.
A 2024 study examining data from 28 European countries (ScienceDirect, Journal of Affective Disorders) found that hearing aid use was associated with significantly reduced likelihood of moderate and severe depression across diverse demographic categories. The hearing–mental health relationship appears to operate primarily through social isolation: individuals who cannot participate fully in conversations progressively reduce their social engagement, with predictable consequences for mood, self-efficacy, and emotional regulation.
A 25-year longitudinal study published in the Journal of Gerontology (Amieva et al., 2018) found that self-reported hearing problems were associated with death, depression, disability, and dementia across a quarter-century of follow-up — providing some of the longest-horizon evidence linking hearing to a broad spectrum of adverse outcomes.
The association between hearing loss and falls is well-documented. A systematic review and meta-analysis by Jiam, Li, and Agrawal (2016, Laryngoscope) found that hearing loss was significantly associated with falls across included studies. The proposed mechanism involves both vestibular co-impairment — cochlear and vestibular structures are anatomically adjacent and often affected simultaneously — and the role of hearing in spatial awareness and postural control.
The Kangbuk Samsung Health Study, a large prospective cohort study examining the association between hearing loss and cause-specific mortality, identified falls and injuries as a statistically significant pathway through which hearing loss elevates injury-related mortality risk, after controlling for demographics and cardiovascular confounders.
For workers in industrial settings, the implications are direct: a worker with moderate untreated hearing loss is not only at elevated risk of audiometric progression — they are at elevated risk of workplace accidents, falls near machinery, and failure to respond to auditory safety signals, as documented in the CDC research cited earlier in this series.
The Canadian cohort study of 4.7 million adults is the most comprehensive examination of the full spectrum of adverse clinical outcomes associated with hearing loss. Beyond mortality, cardiovascular events, and dementia, the study found significantly elevated rates of hospitalization, emergency department visits (both overall and for preventable conditions), placement in long-term care facilities, and adverse drug events among individuals with hearing loss, compared to matched individuals without hearing loss.
The adverse drug event finding deserves specific attention in the occupational context: workers with untreated hearing loss may be less able to receive verbal medication counseling, less likely to understand dosing instructions delivered verbally, and more likely to experience medication errors — creating clinical consequences that extend beyond the workplace into their entire healthcare interaction.
The most rigorous test of whether treating hearing loss can alter the cognitive trajectory is the ACHIEVE randomized controlled trial (Lin et al., 2023, The Lancet). ACHIEVE randomized 977 adults aged 70–84 with untreated hearing loss to hearing intervention (audiological counseling plus hearing aids) or health education control. The primary outcome — 3-year change in global cognition — showed no statistically significant difference between groups in the full sample. However, a pre-specified secondary analysis found that in the ARIC subgroup (participants at higher baseline dementia risk from a cardiovascular health study), hearing intervention reduced 3-year global cognitive decline by 48% compared to controls.
An Australian longitudinal observational study (ENHANCE study, Frontiers in Aging Neuroscience, 2024) following 1,846 participants over 12 years found that hearing aid use was associated with a 19% reduction in cognitive decline rates in those with hearing loss, consistent with the ACHIEVE secondary analysis finding.
The ACHIEVE data, taken together with the observational evidence, suggest that hearing intervention is most effective in individuals who already have elevated dementia risk from other factors — exactly the population that occupational noise-exposed workers over 50 represent. Workers with decades of noise exposure, potential ototoxic chemical co-exposure, and an occupational history documented by serial audiograms are the workers who stand to benefit most from early audiometric detection and clinical referral.
OSHA’s hearing conservation standard was designed to prevent hearing threshold shifts. The research reviewed here establishes that preventing those threshold shifts also prevents, or at least delays, a cascade of downstream health consequences that most employers have never considered part of their HCP’s value proposition.
Early detection through annual audiometric monitoring is the intervention point. A worker whose threshold shift is caught at the STS level — before the loss is functionally significant — has a far shorter path to clinical intervention than a worker who goes untested for years. The audiogram that an employer maintains under OSHA 1910.95 is the document that connects noise exposure to downstream health risk, triggers clinical referral, and starts the treatment clock. An employer who treats that audiogram as a compliance checkbox rather than a health management instrument is operating below the standard of care that the 2024 Lancet Commission now places on the entire healthcare system.
Soundtrace’s annual audiometric monitoring detects threshold shifts early — the intervention window when clinical referral can alter the downstream health trajectory that the Lancet Commission, ACHIEVE, and 50 cohort studies now document clearly.
Get a Free Quote